A combined dataset of human cerebrospinal fluid proteins identified by multi-dimensional chromatography and tandem mass spectrometry

被引:106
作者
Pan, Sheng
Zhu, David
Quinn, Joseph F.
Peskind, Elaine R.
Montjne, Thomas J.
Lin, Biaoyang
Goodlett, David R.
Taylor, Greg
Eng, Jimmy
Zhang, Jing
机构
[1] Univ Washington, Sch Med, Div Neuropathol, Harborview Med Ctr,Dept Pathol, Seattle, WA 98104 USA
[2] Oregon Hlth & Sci Univ, Portland, OR USA
[3] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98104 USA
[4] VA Puget Sound Hlth Care Syst, VA NW Network Mental Illness Res Educ & Clin Ctr, Seattle, WA USA
[5] Inst Syst Biol, Seattle, WA USA
[6] Univ Washington, Dept Med Chem, Seattle, WA 98104 USA
关键词
Alzheimer's disease; human cerebrospinal fluid; mass spectrometry; Parkinson's disease;
D O I
10.1002/pmic.200600756
中图分类号
Q5 [生物化学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
Human cerebrospinal fluid (CSF) is an important source for studying protein biomarkers of agerelated neurodegenerative diseases. Before characterizing biomarkers unique to each disease, it is necessary to categorize CSF proteins systematically and extensively. However, the enormous complexity, great dynamic range of protein concentrations, and tremendous protein heterogeneity due to post-translational modification of CSF create significant challenges to the existing proteomics technologies for an in-depth, nonbiased profiling of the human CSF proteome. To circumvent these difficulties, in the last few years, we have utilized several different separation methodologies and mass spectrometric platforms that greatly enhanced the identification coverage and the depth of protein profiling of CSF to characterize CSF proteome. In total, 2594 proteins were identified in well-characterized pooled human CSF samples using stringent proteomics criteria. This report summarizes our efforts to comprehensively characterize the human CSF proteome to date.
引用
收藏
页码:469 / 473
页数:5
相关论文
共 33 条
[1]
Abdi F, 2006, J ALZHEIMERS DIS, V9, P293
[2]
Mass spectrometry-based proteomics [J].
Aebersold, R ;
Mann, M .
NATURE, 2003, 422 (6928) :198-207
[3]
Perspective: A program to improve protein biomarker discovery for cancer [J].
Aebersold, R ;
Anderson, L ;
Caprioli, R ;
Druker, B ;
Hartwell, L ;
Smith, R .
JOURNAL OF PROTEOME RESEARCH, 2005, 4 (04) :1104-1109
[4]
Peptide mapping of proteins in human body fluids using electrospray ionization Fourier transform ion cyclotron resonance mass spectrometry [J].
Bergquist, J ;
Palmblad, M ;
Wetterhall, M ;
Håkansson, P ;
Markides, KE .
MASS SPECTROMETRY REVIEWS, 2002, 21 (01) :2-15
[5]
PROTEIN-ANALYSIS IN CEREBROSPINAL-FLUID .2. REFERENCE VALUES DERIVED FROM HEALTHY-INDIVIDUALS 18-88 YEARS OF AGE [J].
BLENNOW, K ;
FREDMAN, P ;
WALLIN, A ;
GOTTFRIES, CG ;
KARLSSON, I ;
LANGSTROM, G ;
SKOOG, I ;
SVENNERHOLM, L ;
WIKKELSO, C .
EUROPEAN NEUROLOGY, 1993, 33 (02) :129-133
[6]
Identification of brain cell death associated proteins in human post-mortem cerebrospinal fluid [J].
Burgess, Jennifer A. ;
Lescuyer, Pierre ;
Hainard, Alexandre ;
Burkhard, Pierre R. ;
Turck, Natacha ;
Michel, Philippe ;
Rossier, Joel S. ;
Reymond, Frederic ;
Hochstrasser, Denis F. ;
Sanchez, Jean-Charles .
JOURNAL OF PROTEOME RESEARCH, 2006, 5 (07) :1674-1681
[7]
The need for guidelines in publication of peptide and protein identification data - Working group on publication guidelines for peptide and protein identification data [J].
Carr, S ;
Aebersold, R ;
Baldwin, M ;
Burlingame, A ;
Clauser, K ;
Nesvizhskii, A .
MOLECULAR & CELLULAR PROTEOMICS, 2004, 3 (06) :531-533
[8]
Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects [J].
Castaño, EM ;
Roher, AE ;
Esh, CL ;
Kokjohn, TA ;
Beach, T .
NEUROLOGICAL RESEARCH, 2006, 28 (02) :155-163
[9]
Desiere F, 2005, GENOME BIOL, V6
[10]
Proteomic analysis of cerebrospinal fluid from multiple sclerosis patients [J].
Dumont, D ;
Noben, JP ;
Raus, J ;
Stinissen, P ;
Robben, J .
PROTEOMICS, 2004, 4 (07) :2117-2124